Partner Content Partner Content Boehringer Ingelheim, Novaliq, Santen, Shire, at Europe's Le... SMi’s Leading Ophthalmic Conference
News NICE recommends Bayer drug for severe short-sightedness Eylea should be funded in mCNV, says NICE
Partner Content Partner Content 5 Key Reasons Why You Should Attend Europe's Leading Ophthal... 5 Key Reasons Why You Should Attend
News Novartis next generation eye drug outperforms Eylea Brolucizumab could offer quarterly dosing schedule.
News Novartis takes aim at Shire and Allergan with dry-eye drug Swiss company takes option on Lubris' ECF843.
Oncology CAR-T therapies: Faster, better, cheaper In a new pharmaphorum podcast, editor-in-chief Jonah Comstock speaks with Phil Johnson, MD, president and CEO of Interius Biotherapeutics.
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
